The results of our study suggest that if the current findings are confirmed prospectively, the assessment of p16Ink4a and pRb expression levels may prove to be a useful prognostic factor in advanced-stage ovarian carcinomas after standardised chemotherapy including completely debulked patients. The gene discussed is CDKN2A; the disease is ovarian carcinoma.